INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on August 14, 2023, by INVO Bioscience, Inc. (Nasdaq: INVO), a Nevada corporation. The filing serves to announce the Company's financial results for the period ended June 30, 2023, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the source text.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the body of this 8-K filing. The document solely references the issuance of the results announcement.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other Company filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2023) for actual financial figures and operational highlights.
- Verify the Company's cash position and runway given the lack of specific liquidity data in this summary filing.
- Check for any subsequent filings that may incorporate the results by reference.
- Confirm the trading status of INVO on The Nasdaq Stock Market LLC.